Oric Pharmaceuticals, Inc. (ORIC) stock
ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.86−0.64 (-7.53%)
Close on Nov 13, 2026Market cap $814.71MP/E –Yield –
Oric Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Oric Pharmaceuticals's cash was $264.76M at Jun 30, 2026. For fiscal 2025 it was $281.49M, up 9.8% from the year before. The highest annual figure on record is $293.60M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $281.49M | +9.8% |
| FY2024 | Dec 31, 2024 | $256.45M | +22.9% |
| FY2023 | Dec 31, 2023 | $208.68M | +0.9% |
| FY2022 | Dec 31, 2022 | $206.74M | -12.9% |
| FY2021 | Dec 31, 2021 | $237.45M | -19.1% |
| FY2020 | Dec 31, 2020 | $293.60M | +229.3% |
| FY2019 | Dec 31, 2019 | $89.16M | +109.1% |
| FY2018 | Dec 31, 2018 | $42.64M | +65.1% |
| FY2017 | Dec 31, 2017 | $25.82M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $264.76M | -6.3% |
| Q1 FY2026 | Mar 31, 2026 | $281.93M | +38.4% |
| Q4 FY2025 | Dec 31, 2025 | $281.49M | +9.8% |
| Q3 FY2025 | Sep 30, 2025 | $287.14M | +5.4% |
| Q2 FY2025 | Jun 30, 2025 | $282.51M | -1.4% |
| Q1 FY2025 | Mar 31, 2025 | $203.72M | -35.7% |
| Q4 FY2024 | Dec 31, 2024 | $256.45M | +22.9% |
| Q3 FY2024 | Sep 30, 2024 | $272.37M | +19.8% |
| Q2 FY2024 | Jun 30, 2024 | $286.41M | +8.4% |
| Q1 FY2024 | Mar 31, 2024 | $316.78M | +67.1% |
| Q4 FY2023 | Dec 31, 2023 | $208.68M | +0.9% |
| Q3 FY2023 | Sep 30, 2023 | $227.30M | +17.4% |
| Q2 FY2023 | Jun 30, 2023 | $264.16M | +16.3% |
| Q1 FY2023 | Mar 31, 2023 | $189.63M | -19.2% |
| Q4 FY2022 | Dec 31, 2022 | $206.74M | -12.9% |
| Q3 FY2022 | Sep 30, 2022 | $193.66M | -33.1% |
| Q2 FY2022 | Jun 30, 2022 | $227.06M | -13.0% |
| Q1 FY2022 | Mar 31, 2022 | $234.62M | -15.6% |
| Q4 FY2021 | Dec 31, 2021 | $237.45M | -19.1% |
| Q3 FY2021 | Sep 30, 2021 | $289.52M | +55.1% |
| Q2 FY2021 | Jun 30, 2021 | $261.07M | +32.8% |
| Q1 FY2021 | Mar 31, 2021 | $278.14M | +250.1% |
| Q4 FY2020 | Dec 31, 2020 | $293.60M | +229.3% |
| Q3 FY2020 | Sep 30, 2020 | $186.61M | +93.5% |
| Q2 FY2020 | Jun 30, 2020 | $196.64M | +104.2% |
| Q1 FY2020 | Mar 31, 2020 | $79.44M | +52.0% |
| Q4 FY2019 | Dec 31, 2019 | $89.16M | +109.1% |
| Q3 FY2019 | Sep 30, 2019 | $96.42M | +273.5% |
| Q2 FY2019 | Jun 30, 2019 | $96.31M | – |
| Q1 FY2019 | Mar 31, 2019 | $52.27M | – |
| Q4 FY2018 | Dec 31, 2018 | $42.64M | – |
| Q4 FY2017 | Dec 31, 2017 | $25.82M | – |
See a number that looks wrong?